FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206263116> ?p ?o ?g. }

• W3206263116 endingPage "S1148" @default.
• W3206263116 startingPage "S1147" @default.
• W3206263116 abstract "For patients with metastatic disease, identification of both the primary tumor type and molecular alterations increases eligibility for targeted therapies. The 92-gene assay (CancerTYPE ID) is a validated gene expression classifier of 50 tumor types and subtypes for metastatic patients with unknown or uncertain diagnoses. Multimodal biomarker testing identifies actionable alterations to guide therapy selection. Here, a database of metastatic cases integrating molecular cancer classification with secondary biomarker analysis was analyzed to assess clinical utility in patients with lung cancer with known histology but unknown primary site of origin. MOSAIC (Molecular Synergy to Advance Individualized Cancer Care) is an IRB-approved, de-identified database of metastatic cases with unknown or uncertain diagnoses submitted for CancerTYPE ID testing and tissue type-guided multimodal biomarker testing (NeoTYPE profiles, Neogenomics). Metastatic cancers classified as adenocarcinoma, squamous cell carcinoma (SqCC), carcinoid and small/large cell carcinoma were evaluated by next-generation sequencing (NGS), fluorescent in situ hybridization (FISH) and immunohistochemical (IHC) analyses to identify primary site of tumor. Molecular diagnoses by CancerTYPE ID of 2151 patients included 271 (12.6%) with non-small cell lung carcinoma features [NSCLC; 157 lung adenocarcinomas (7.3%), 114 SqCCs (5.3%)], 10 (0.5%) lung carcinoid tumors and 71 (3.3%) with small/large cell carcinoma features. Gene fusion analysis by FISH identified 5 ALK (5.9%), 5 MET (6.0%), 1 RET (1.2%), and 1 ROS1 (1.2%) alterations in adenocarcinoma, as well as 2 MET alterations (3.4%) in SqCC. The mutational frequency of the 10 most commonly mutated genes for each lung cancer subtype are shown in Table 1. Mutations identified included genes for which targeted therapies are available, including capmatinib for MET exon 14 skipping mutations and dabrafenib for BRAF V600E mutations. Multimodal biomarker testing for pan-TRK identified 1 (1.5%) lung adenocarcinoma, 7 (15.2%) SqCC and 6 (24.0%) small/large cell carcinoma cases, which were eligible for larotrectinib and entrectinib. PD-L1 expression was seen in 95 (83.3%) lung adenocarcinoma, 58 (74.4%) SqCC, 5 (62.5%) lung carcinoid and 32 (62.8%) small/large cell carcinoma cases.Table 1Top 10 gene mutations frequency by NGSMain Type (Subtype)Top 10 Gene Mutations Detected by NGSNSCLCLung AdenocarcinomaTP53KRASKEAP1KMT2DSTK11ARID2BRCA2CHD2EPHA5KMT2C65.6%41.9%26.7%20.0%15.6%14.3%14.3%14.3%14.3%14.3%Squamous Cell Carcinoma (Lung)TP53KMT2DARID1ASMARCA4FAT1PIK3CAKEAP1LRP1BMTORNTRK371.0%32.4%23.5%23.5%22.2%20.0%17.7%16.7%16.7%16.7%OtherNeuroendocrine (lung carcinoid)*----------Neuroendocrine Small/large cell lung carcinomaTP53CTNNB1APCDICER1RANBP2RB1RUNX1SETD2SMARCA4TSC267.4%27.3%18.2%18.2%18.2%18.2%18.2%18.2%18.2%18.2%*low case number, unable to analyze; % indicated cases with detected gene abnormalities out of all cases with available test results. Open table in a new tab *low case number, unable to analyze; % indicated cases with detected gene abnormalities out of all cases with available test results. Analysis of the MOSAIC database identified a subset of patients with metastatic cancers eligible for lung cancer directed targeted therapy and immunotherapy based on tumor type, genetic alterations, and PD-L1 expression. Molecular profiling combined with cancer classification may lead to improved therapy options for patients with advanced disease of unknown primary and may provide further evidence for subsequent combination trials of targeted therapies or immunotherapies to improve patient outcomes." @default.
• W3206263116 created "2021-10-25" @default.
• W3206263116 creator A5002982469 @default.
• W3206263116 creator A5022339242 @default.
• W3206263116 creator A5052057289 @default.
• W3206263116 creator A5056657552 @default.
• W3206263116 creator A5062968216 @default.
• W3206263116 creator A5079761595 @default.
• W3206263116 date "2021-10-01" @default.
• W3206263116 modified "2023-09-29" @default.
• W3206263116 title "P59.05 Integration of Molecular Cancer Classification and NGS to Identify Metastatic Cancer Patients Eligible For Lung Cancer Directed Therapy" @default.
• W3206263116 doi "https://doi.org/10.1016/j.jtho.2021.08.594" @default.
• W3206263116 hasPublicationYear "2021" @default.
• W3206263116 type Work @default.
• W3206263116 sameAs 3206263116 @default.
• W3206263116 citedByCount "0" @default.
• W3206263116 crossrefType "journal-article" @default.
• W3206263116 hasAuthorship W3206263116A5002982469 @default.
• W3206263116 hasAuthorship W3206263116A5022339242 @default.
• W3206263116 hasAuthorship W3206263116A5052057289 @default.
• W3206263116 hasAuthorship W3206263116A5056657552 @default.
• W3206263116 hasAuthorship W3206263116A5062968216 @default.
• W3206263116 hasAuthorship W3206263116A5079761595 @default.
• W3206263116 hasBestOaLocation W32062631161 @default.
• W3206263116 hasConcept C121608353 @default.
• W3206263116 hasConcept C126322002 @default.
• W3206263116 hasConcept C142724271 @default.
• W3206263116 hasConcept C143998085 @default.
• W3206263116 hasConcept C2776256026 @default.
• W3206263116 hasConcept C2777546739 @default.
• W3206263116 hasConcept C2781182431 @default.
• W3206263116 hasConcept C2781197716 @default.
• W3206263116 hasConcept C2781230642 @default.
• W3206263116 hasConcept C502942594 @default.
• W3206263116 hasConcept C55493867 @default.
• W3206263116 hasConcept C71924100 @default.
• W3206263116 hasConcept C86803240 @default.
• W3206263116 hasConceptScore W3206263116C121608353 @default.
• W3206263116 hasConceptScore W3206263116C126322002 @default.
• W3206263116 hasConceptScore W3206263116C142724271 @default.
• W3206263116 hasConceptScore W3206263116C143998085 @default.
• W3206263116 hasConceptScore W3206263116C2776256026 @default.
• W3206263116 hasConceptScore W3206263116C2777546739 @default.
• W3206263116 hasConceptScore W3206263116C2781182431 @default.
• W3206263116 hasConceptScore W3206263116C2781197716 @default.
• W3206263116 hasConceptScore W3206263116C2781230642 @default.
• W3206263116 hasConceptScore W3206263116C502942594 @default.
• W3206263116 hasConceptScore W3206263116C55493867 @default.
• W3206263116 hasConceptScore W3206263116C71924100 @default.
• W3206263116 hasConceptScore W3206263116C86803240 @default.
• W3206263116 hasIssue "10" @default.
• W3206263116 hasLocation W32062631161 @default.
• W3206263116 hasOpenAccess W3206263116 @default.
• W3206263116 hasPrimaryLocation W32062631161 @default.
• W3206263116 hasRelatedWork W1482345510 @default.
• W3206263116 hasRelatedWork W1855101007 @default.
• W3206263116 hasRelatedWork W2274156351 @default.
• W3206263116 hasRelatedWork W2376684597 @default.
• W3206263116 hasRelatedWork W2387455091 @default.
• W3206263116 hasRelatedWork W2403361534 @default.
• W3206263116 hasRelatedWork W2743740828 @default.
• W3206263116 hasRelatedWork W3046154081 @default.
• W3206263116 hasRelatedWork W3171615116 @default.
• W3206263116 hasRelatedWork W4200188553 @default.
• W3206263116 hasVolume "16" @default.
• W3206263116 isParatext "false" @default.
• W3206263116 isRetracted "false" @default.
• W3206263116 magId "3206263116" @default.
• W3206263116 workType "article" @default.